

IFW



Patent Application
Attorney Docket No. PC25541A

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Hon. Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 16 day of November, 2004.

By Erica L. Smith
(Signature of person mailing)
Erica L. Smith
(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Philip A. Carpino et al. :
APPLICATION NO.: 10/823,107 : Examiner:
FILING DATE: April 12, 2004 : Group Art Unit: 1614
TITLE: Cannabinoid Receptor Ligands and Uses Thereof :

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.


Applicants herein make available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicants, copies of which are enclosed.

Under 37 C.F.R. 1.97(e)(1), I hereby certify that each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this statement.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

The Examiner is respectfully requested to indicate his or her consideration of the foregoing items by initialing, signing, and dating the accompanying PTO-FB-A820 and then returning a copy of the same to the undersigned. It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.



Date:

November 10, 2004


Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871

Patent Application
Attorney Docket No. PC25541A

Respectfully submitted,

Arlene K. Musser

Arlene K. Musser
Attorney for Applicant(s)
Reg. No. 37,895



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC25541A	SERIAL NO. 10/823,107
	APPLICANT Philip A. Carpino et al.	
	FILING DATE April 12, 2004	GROUP 1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	4	4	9	0	5	4	1	12/25/84	Ellingsfeld, et al.	548	370	
	US	3	5	2	6	6	3	3	9/1/70	Gadekar, et al.	260	295	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	9	9	4	6	2	6	7	9/16/99	International	C07D	513/04		
	WO	0	1	5	8	8	6	9	8/16/01	International	C07D	209/42		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

				Pertwee, R., <u>Exp. Opin. Invest. Drugs</u> , "Cannabinoid Receptor Ligands: Clinical and Neuropharmacological Considerations, Relevant to Future Drug Discovery and Development", Vol. 9(7), pages 1553-1571 (2000)									

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.